In parallel with the prelim clinical data from the three trials in different indications, there will be the pre-clinical data from CDH17 expressing solid tumours via both Autologous Car-T and Allogeniec Car-NK. All eyes in the industry will be on CHM and hence why (perhaps) the timing and preemptive CR plan.
Ann: First patient enrolled in CHM CDH17 Phase 1/2 clinical trial, page-25
-
- There are more pages in this discussion • 12 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CHM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $12.67M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
| CHM (ASX) Chart |
Day chart unavailable